Tag Archives: Gbola Amusa

Chardan Capital Reaffirms Their Buy Rating on Provention Bio (PRVB)

In a report released today, Gbola Amusa from Chardan Capital reiterated a Buy rating on Provention Bio (PRVB – Research Report), with a price target of $40.00. The company’s shares closed last Monday at $15.58. According to TipRanks.com, Amusa is

Axovant Gene Therapies (AXGT) Receives a Rating Update from a Top Analyst

In a report released today, Gbola Amusa from Chardan Capital reiterated a Buy rating on Axovant Gene Therapies (AXGT – Research Report), with a price target of $15.00. The company’s shares closed last Wednesday at $3.40. According to TipRanks.com, Amusa

Adverum Biotechnologies (ADVM) Received its Third Buy in a Row

After SunTrust Robinson and Piper Sandler gave Adverum Biotechnologies (NASDAQ: ADVM) a Buy rating last month, the company received another Buy, this time from Chardan Capital. Analyst Gbola Amusa reiterated a Buy rating on Adverum Biotechnologies today. The company’s shares

Analysts Offer Insights on Healthcare Companies: Passage Bio (NASDAQ: PASG) and Cytokinetics (NASDAQ: CYTK)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Passage Bio (PASG – Research Report) and Cytokinetics (CYTK – Research Report) with bullish sentiments. Passage Bio (PASG) Chardan Capital analyst Gbola

Voyager Therapeutics (VYGR) Receives a Hold from Chardan Capital

Chardan Capital analyst Gbola Amusa reiterated a Hold rating on Voyager Therapeutics (VYGR – Research Report) on May 6 and set a price target of $15.00. The company’s shares closed last Friday at $11.15. According to TipRanks.com, Amusa is a

Chardan Capital Keeps a Buy Rating on Adverum Biotechnologies (ADVM)

Chardan Capital analyst Gbola Amusa reiterated a Buy rating on Adverum Biotechnologies (ADVM – Research Report) on May 5 and set a price target of $20.00. The company’s shares closed last Friday at $19.59. According to TipRanks.com, Amusa is a